Freeline to Host Virtual KOL Event on its Gene Therapy Candidate, FLT201, in Gaucher Disease

Webinar to take place on August 1, 2023, at 8:30 AM ET

LONDON, July 25, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced it will host a virtual Key Opinion Leader (KOL) event on FLT201, its adeno-associated virus (AAV) gene therapy candidate in Gaucher disease Type 1, on Tuesday, August 1, 2023 at 8:30 a.m. ET.

The event will feature Gaucher disease expert, Dr. Reena Sharma, Consultant Adult Metabolic Medicine and Honorary Senior Lecturer at the Salford Royal Hospital in the United Kingdom, who will discuss the epidemiology, treatment landscape, and unmet need in Gaucher disease.

The Freeline leadership team will provide a corporate overview and outline the clinical progress of FLT201. Currently, FLT201 is being evaluated in the GALILEO-1 study, a first-in-human, international, multicenter Phase 1/2 dose-escalation trial assessing safety, tolerability and efficacy of a single intravenous dose of FLT201, with the aim of identifying a dose for further development in a Phase 3 clinical trial. Dosing commenced in the trial last month.

A live question and answer session will follow the formal presentations. To access the event, participants may register here. While not required, it is recommended that participants join 10 minutes prior to the scheduled start. A live webcast of the event will be available on the Investors section of Freeline’s website at www.freeline.life. An archived replay will be available on the website for at least 90 days.

About Gaucher Disease
Gaucher disease is caused by a mutation in the GBA1 gene that results in abnormally low levels of glucocerebrosidase (GCase), an enzyme needed to metabolize a certain type of lipid. As a result, harmful substrates glucosylceramide (Gb-1) and glucosylsphingosine (lyso-Gb1) build up in cells that then accumulate in various organs, causing inflammation and dysfunction. Gaucher disease is hereditary and presents in various subtypes. Freeline is currently focused on Gaucher disease type 1, the most common form of the disease, which affects the health of the spleen, liver, bone and lungs. Despite treatment with existing therapies, many people with Gaucher disease continue to experience symptoms and disease progression. Gaucher disease affects approximately 18,000 people in the United States, United Kingdom, France, Germany, Spain, Italy and Israel.